Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIA 33
- Development stage
- Preclinical
- Lead developer
- Bial
01
Overview
BIA 33 is an early-stage preclinical drug candidate being developed by BIAL-Portela & Cia SA (Bial) for the treatment of rare diseases. As a research-stage compound, specific details regarding its molecular modality, biological target, and exact mechanism of action have not been publicly disclosed by the developer. The program is part of Bial's strategic expansion into the rare disease therapeutic area, complementing its established portfolio in central nervous system disorders such as Parkinson's disease and epilepsy. Currently, the drug remains in the preclinical phase of development with minimal public information available regarding its therapeutic profile.
Beyond the preview
Go deeper on BIA 33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIA 33.